盐诱导激酶1与肿瘤

国际肿瘤学杂志››2017,Vol. 44››Issue (11): 838-841.doi:10.3760/cma.j.issn.1673-422X.2017.11.008

刘大威，贺德

524023 湛江，广东医科大学研究生院（刘大威）；南方医科大学附属深圳宝安医院普通外科（刘大威、贺德）

收稿日期:2017-04-10出版日期:2017-11-08发布日期:2017-11-24
通讯作者:贺德 E-mail:hede1965@126.com
基金资助:

深圳市科技计划（JCYJ20160427192617570）

Salt-induced kinase 1 and tumors

Liu Dawei, He De

Department of General Surgery, Affiliated Bao′an Hospital of Southern Medical University, Shenzhen 518101, China

Received:2017-04-10Online:2017-11-08Published:2017-11-24
Contact:贺德 E-mail:hede1965@126.com
Supported by:

Science and Technology Project of Shenzhen of China (JCYJ20160427192617570)

摘要/Abstract

摘要：盐诱导激酶1（SIK1）与肿瘤的发生密切相关。研究表明SIK1在肝癌、胰腺癌、胃癌、肺癌、卵巢癌等肿瘤中的表达具有特异性，其异常表达能够抑制或促进肿瘤的发生、发展和转移。异常表达的SIK1有望为肿瘤的诊断和治疗提供新的方法，并对临床预后提供指导。

刘大威，贺德. 盐诱导激酶1与肿瘤[J]. 国际肿瘤学杂志, 2017, 44(11): 838-841.

刘大威，贺德. Salt-induced kinase 1 and tumors[J]. Journal of International Oncology, 2017, 44(11): 838-841.

［1］ Du WQ, Zheng JN, Pei DS. The diverse oncogenic and tumor suppressor roles of saltinducible kinase (SIK) in cancer［J］. Expert Opin Ther Targets, 2016, 20(4): 477-485. DOI: 10.1517/14728222.2016.1101452. ［2］ Finsterwald C, Carrard A, Martin JL. Role of saltinducible kinase 1 in the activation of MEF2dependent transcription by BDNF［J］. PLoS One, 2013, 8(1): e54545. DOI: 10.1371/journal.pone.0054545. ［3］ Nixon M, StewartFitzgibbon R, Fu J, et al. Skeletal muscle salt inducible kinase 1 promotes insulin resistance in obesity［J］. Mol Metab, 2016, 5(1): 34-46. DOI: 10.1016/j.molmet.2015.10.004. ［4］ Kim MJ, Park SK, Lee JH, et al. Saltinducible kinase 1 terminates cAMP signaling by an evolutionarily conserved negativefeedback loop in βcells［J］. Diabetes, 2015, 64(9): 31893202. DOI: 10.2337/db141240. ［5］ Bertorello AM, Pires N, Igreja B, et al. Increased arterial blood pressure and vascular remodeling in mice lacking salt inducible kinase 1 (SIK1)［J］. Circ Res, 2015, 116(4): 642652. DOI: 10.1161/CIRCRESAHA.116.304529. ［6］ Eneling K, Chen J, Welch LC, et al. Saltinducible kinase 1 is present in lung alveolar epithelial cells and regulates active sodium transport［J］. Biochem Biophys Res Commun, 2011, 409(1): 28-33. DOI: 10.1016/j.bbrc.2011.04.100. ［7］ Qu C, He D, Lu X, et al. Saltinducible kinase (SIK1) regulates HCC progression and WNT/βcatenin activation［J］. J Hepatol, 2016, 64(5): 1076-1089. DOI: 10.1016/j.jhep.2016.01.005. ［8］ Qu C, Qu Y. Downregulation of saltinducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis［J］. Oncotarget, 2017, 8(2): 31443155. DOI: 10.18632/oncotarget.13673. ［9］ Zou YF, Xie CW, Yang SX, et al. AMPK activators suppress breast cancer cell growth by inhibiting DVL3facilitated Wnt/βcatenin signaling pathway activity［J］. Mol Med Rep, 2017, 15(2): 899-907. DOI: 10.3892/mmr.2016.6094. ［10］ Chen Y, Huang Q, Zhou H, et al. Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)mediated cytotoxic effects on renal carcinoma cells［J］. Oncotarget, 2016, 7(31): 50401-50416. DOI: 10.18632/oncotarget.10409. ［11］ Fan D, Ren B, Yang X, et al. Upregulation of miR5015p activates the wnt/betacatenin signaling pathway and enhances stem celllike phenotype in gastric cancer［J］. J Exp Clin Cancer Res, 2016, 35(1): 177. DOI: 10.1186/s13046-016-0432-x. ［12］ Klose J, Eissele J, Volz C, et al. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/betacatenin signaling in CD133+ human colorectal cancer cells［J］. BMC Cancer, 2016, 16(1): 896. DOI: 10.1186/s12885-016-2879-8. ［13］ Liu Y, Gao S, Chen X, et al. Overexpression of miR203 sensitizes paclitaxel (Taxol)resistant colorectal cancer cells through targeting the saltinducible kinase 2 (SIK2)［J］. Tumour Biol, 2016, 37(9): 1223112239. DOI: 10.1007/s13277-016-5066-2. ［14］ Miranda F, Mannion D, Liu S, et al. Saltinducible kinase 2 couples ovarian cancer cell metabolism with survival at the adipocyterich metastatic niche［J］. Cancer Cell, 2016, 30(2): 273289. DOI: 10.1016/j.ccell.2016.06.020. ［15］ Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008［J］. CA Cancer J Clin, 2012, 62(2): 118-128. DOI: 10.1016/j.juro.2012.06.090. ［16］ Ren ZG, Dong SX, Han P, et al. miR203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer［J］. Oncol Rep, 2016, 35(3): 1365-1374. DOI: 10.3892/or.2015.4534. ［17］魏永永，侯静，唐文如，等. p53与Ras协同及其在肿瘤发生中的作用［J］. 遗传, 2012, 34（12）: 15131521. DOI: 10.3724/SP.J.1005.2012.01513. ［18］ Witte D, Zeeh F, Gdeken T, et al. Proteinaseactivated receptor 2 is a novel regulator of TGFβ signaling in pancreatic cancer［J］. J Clin Med, 2016, 5(12): 111. DOI: 10.3390/jcm5120111. ［19］ Demagny H, De Robertis EM. Point mutations in the tumor suppressor Smad4/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGFbeta signaling［J］. Mol Cell Oncol, 2016, 3(1): e1025181. DOI: 10.1080/23723556.2015.1025181. ［20］ Steigedal TS, Prestvik WS, Selvik LK, et al. Gastrininduced proliferation involves MEK partner 1 (MP1)［J］. In Vitro Cell Dev Biol Anim, 2013, 49(3): 162-169. DOI: 10.1007/s1162601395882. ［21］ Selvik LK, Rao S, Steigedal TS, et al. Saltinducible kinase 1 (SIK1) is induced by gastrin and inhibits migration of gastric adenocarcinoma cells［J］. PLoS One, 2014, 9(11): e112485. DOI: 10.1371/journal.pone.0112485. ［22］ Chen JL, Chen F, Zhang TT, et al. Suppression of SIK1 by miR141 in human ovarian cancer cell lines and tissues［J］. Int J Mol Med, 2016, 37(6): 1601-1610. DOI: 10.3892/ijmm.2016.2553. ［23］ Xu J, Wu W, Wang J, et al. miR367 promotes the proliferation and invasion of nonsmall cell lung cancer via targeting FBXW7［J］. Oncol Rep, 2017, 37(2): 1052-1058. DOI: 10.3892/or.2016.5314. ［24］ Meng X, Lu P, Fan Q. miR367 promotes proliferation and invasion of hepatocellular carcinoma cells by negatively regulating PTEN［J］. Biochem Biophys Res Commun, 2016, 470(1): 187191. DOI: 10.1016/j.bbrc.2016.01.025. ［25］ Chen W, Zheng R, Zeng H, et al. The updated incidences and mortalities of major cancers in China, 2011［J］. Chin J Cancer, 2015, 34(11): 502-507. DOI: 10.1186/s40880-015-0042-6. ［26］ Yao YH, Cui Y, Qiu XN, et al. Attenuated LKB1SIK1 signaling promotes epithelialmesenchymal transition and radioresistance of nonsmall cell lung cancer cells［J］. Chin J Cancer, 2016, 35: 50. DOI: 10.1186/s4088001601133. ［27］ Shaw RJ. Tumor suppression by LKB1: SIKness prevents metastasis［J］. Sci Signal, 2009, 2(86): e55. DOI: 10.1126/scisignal.286pe55. ［28］ Bai L, Lin G, Sun L, et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of nonsmall cell lung cancer via the ERK1/2/MMP9 pathway［J］. Oncotarget, 2016, 7(26): 40377-40386. DOI: 10.18632/oncotarget.9750. ［29］ Yang N, Cui H, Han F, et al. Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP9 and ERK signaling［J］. Oncol Lett, 2016, 12(2): 1471-1476. DOI: 10.3892/ol.2016.4761.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.